Furthermore, high LOX expression in patients’ plasma was found to be associated with statistically significant worse OS and EFS in AML patients under the age of 60 years in a univariate setting – a finding which we found to be even more pronounced in the patient group with reported extramedullary AML. The gene discussed is LOX; the disease is acute myeloid leukemia.